Want to see JP:4880 full AI Analyst Report?
CellSource Co., Ltd. (4880) AI Stock Analysis
CellSource Co., Ltd.
(TSE/TYO:4880)
The overall score is constrained by a severe collapse in profitability, which undermines an otherwise fortress-like balance sheet. The extremely high P/E ratio of 97.19 is a major red flag given the 0.3% net margin. While recent cash flow improvements and short-term price momentum offer some support, the company's inability to convert revenue growth into sustainable earnings is the most significant risk factor.
CellSource Co., Ltd. (4880) vs. iShares MSCI Japan ETF (EWJ)
- Market Cap
- JPY 5.62B
- Dividend Yield
- 1.75%
- Average Volume (3M)
- 61.33K
- Price to Earnings (P/E)
- 56.9
- Beta (1Y)
- 0.94
- Revenue Growth
- -9.94%
- EPS Growth
- ―
- Country
- Japan
- Employees
- 148
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
CellSource Co., Ltd. Business Overview & Revenue Model
Company Description
CellSource Co., Ltd. operates within both the regenerative medicine and consumer product sectors. Among its offerings is Signalift, an anti-aging solution. The company, which was established in 2015, is headquartered in Tokyo, Japan.
CellSource Co., Ltd. Financial Statement Overview
Summary
Financial performance is mixed. The balance sheet is very strong with minimal debt and high equity (Score 75), but the income statement reveals severe profitability deterioration with net margins collapsing to 0.3% (Score 25). Cash flow shows a massive 457% surge, but from a very low base (Score 55). The overall financial health is constrained by the inability to convert revenue growth into earnings.
Income Statement
25NegativeBalance Sheet
75PositiveCash Flow
55Neutral| Breakdown | TTM | Oct 2025 | Oct 2024 | Oct 2023 | Oct 2022 | Oct 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.67B | 3.71B | 4.36B | 4.51B | 4.27B | 2.92B |
| Gross Profit | 2.11B | 2.09B | 2.36B | 3.16B | 3.05B | 2.06B |
| EBITDA | 469.11M | 371.03M | 282.38M | 1.29B | 1.63B | 1.05B |
| Net Income | 70.68M | 10.66M | 237.94M | 923.14M | 1.02B | 651.40M |
Balance Sheet | ||||||
| Total Assets | 6.98B | 7.11B | 7.17B | 6.89B | 4.60B | 3.37B |
| Cash, Cash Equivalents and Short-Term Investments | 4.79B | 4.71B | 4.32B | 4.78B | 3.12B | 2.41B |
| Total Debt | 25.26M | 56.72M | 77.29M | 97.54M | 0 | 1.10M |
| Total Liabilities | 991.71M | 1.10B | 1.13B | 689.49M | 815.72M | 645.58M |
| Stockholders Equity | 5.99B | 6.02B | 6.04B | 6.20B | 3.79B | 2.72B |
Cash Flow | ||||||
| Free Cash Flow | 289.90M | 289.90M | 98.47M | 498.62M | 752.89M | 843.36M |
| Operating Cash Flow | 333.10M | 333.10M | 591.72M | 846.69M | 847.60M | 898.19M |
| Investing Cash Flow | -3.29M | -3.29M | -614.96M | -624.08M | -169.39M | -256.12M |
| Financing Cash Flow | 61.07M | 61.07M | -437.24M | 1.45B | 14.42M | 9.35M |
CellSource Co., Ltd. Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4880, the sentiment is Negative. The current price of 283.00 is below the 20-day moving average (MA) of 308.45, below the 50-day MA of 324.00, and below the 200-day MA of 354.64, indicating a bearish trend. The MACD of -8.66 indicates Positive momentum. The RSI at 29.34 is Positive, neither overbought nor oversold. The STOCH value of 5.66 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4880.
CellSource Co., Ltd. Peers Comparison
Overall Rating
- JP:488050Neutral
JP:459348Neutral
JP:497843Neutral
JP:459942Neutral
JP:777442Neutral
JP:777637Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| JP:4880 | 50Neutral | JPY 5.68B | 56.94 | ― | 1.75% | -9.94% | ― |
| JP:4593 | 48Neutral | JPY 37.00B | 52.62 | ― | ― | -47.32% | ― |
| JP:4978 | 43Neutral | JPY 13.03B | -25.93 | ― | ― | -18.71% | -246.54% |
| JP:4599 | 42Neutral | JPY 8.71B | -4.51 | ― | ― | ― | 4.85% |
| JP:7774 | 42Neutral | JPY 25.54B | -54.89 | ― | ― | 17.05% | 10.47% |
| JP:7776 | 37Underperform | JPY 7.43B | -6.32 | ― | ― | -56.16% | 3.12% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| JP:4880 | CellSource Co., Ltd. | 283.00 | -228.00 | -44.62% | |
| JP:4593 | Healios KK | 261.00 | -233.00 | -47.17% | |
| JP:4599 | StemRIM Inc. | 134.00 | -139.00 | -50.92% | |
| JP:4978 | ReproCELL Inc. | 119.00 | -54.00 | -31.21% | |
| JP:7774 | Japan Tissue Engineering Co., Ltd. | 595.00 | 119.00 | 25.00% | |
| JP:7776 | CellSeed Inc. | 183.00 | -254.00 | -58.12% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 06, 2026